CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cirius Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cirius Therapeutics Inc
12651 High Bluff Drive, Suite 150
Phone: (858) 333-6274p:858 333-6274 San Diego, CA  92130  United States Fax: (302) 655-5049f:302 655-5049
Business Summary
Cirius Therapeutics Inc is a United States-based clinical-stage pharmaceutical company, which is engaged in development and commercialization of therapies for the treatment of liver and metabolic diseases. The Company's products, such as, MSDC-0602K. MSDC-0602K is an insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-6062K in the EMMINENCE trial (Phase II b) clinical trial to evaluate the compound’s safety, tolerability and efficacy in patients with NASH. The EMMINENCE trial is a study of three doses of MSDC-0602K (62.5, 125 and 250 milligram) or placebo given orally, once daily, for a period of one year to subjects with biopsy NASH with fibrosis.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201812/31/2018YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Business Names
Business Name
Cirius Therapeutics Inc
CSTX
Octeta Therapeutics

General Information
Number of Employees: 11 (As of 12/31/2018)
Outstanding Shares: 82,307,449 (As of 2/13/2019)
Stock Exchange: NASD
Federal Tax Id: 820928811
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023